PARP inhibitors such as Olaparib are in use in the clinic to treat breast and ovarian cancers that are deficient in BRCA1 or BRCA2, encoded by genes associated with inherited susceptibility to breast cancer (Slade, 2020). Here, PARP1 is linked to breast cancer.